Giuseppe Andò1, Francesco Costa2. 1. Department of Clinical and Experimental Medicine, University of Messina, Italy. Electronic address: giuseppeando1975@gmail.com. 2. Department of Clinical and Experimental Medicine, University of Messina, Italy.
Abstract
AIMS: Double or triple antithrombotic therapy (DAT/TAT) including or excluding aspirin in association with oral anticoagulant and P2Y12 inhibitor are currently two available options in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). We evaluated efficacy and safety outcomes for DAT vs. TAT. METHODS AND RESULTS: Four non-vitamin K oral anticoagulants (NOAC)-based randomized controlled trials comparing DAT vs. TAT with a total of 10,938 patients were pooled. Bleeding events occurred more frequently than ischemic events. DAT as compared to TAT was associated to an increased risk of stent thrombosis (RR 1.54, 95% CI 1.10-2.14; p = 0.03), myocardial infarction (RR 1.23, 95% CI 1.04-1.46; p = 0.03) and cardiovascular mortality (RR 1.09, 95% CI 1.01-1.19; p = 0.04) and to a reduced risk of ISTH major or clinically relevant non-major bleeding (RR 0.59, 95% CI 0.62-0.93; p = 0.03). A consistent effect was observed in all safety endpoints. Intracranial haemorrhage was numerically reduced by DAT. No difference for all-cause death was observed. CONCLUSION: Antithrombotic treatment in patients with AF undergoing PCI represents a trade-off between ischemia and bleeding. A careful patient selection based on baseline ischemic and bleeding risk may optimize the net clinical balance in this population.
AIMS: Double or triple antithrombotic therapy (DAT/TAT) including or excluding aspirin in association with oral anticoagulant and P2Y12 inhibitor are currently two available options in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). We evaluated efficacy and safety outcomes for DAT vs. TAT. METHODS AND RESULTS: Four non-vitamin K oral anticoagulants (NOAC)-based randomized controlled trials comparing DAT vs. TAT with a total of 10,938 patients were pooled. Bleeding events occurred more frequently than ischemic events. DAT as compared to TAT was associated to an increased risk of stent thrombosis (RR 1.54, 95% CI 1.10-2.14; p = 0.03), myocardial infarction (RR 1.23, 95% CI 1.04-1.46; p = 0.03) and cardiovascular mortality (RR 1.09, 95% CI 1.01-1.19; p = 0.04) and to a reduced risk of ISTH major or clinically relevant non-major bleeding (RR 0.59, 95% CI 0.62-0.93; p = 0.03). A consistent effect was observed in all safety endpoints. Intracranial haemorrhage was numerically reduced by DAT. No difference for all-cause death was observed. CONCLUSION: Antithrombotic treatment in patients with AF undergoing PCI represents a trade-off between ischemia and bleeding. A careful patient selection based on baseline ischemic and bleeding risk may optimize the net clinical balance in this population.
Authors: Alessandro Caracciolo; Renato Francesco Maria Scalise; Fabrizio Ceresa; Gianluca Bagnato; Antonio Giovanni Versace; Roberto Licordari; Silvia Perfetti; Francesca Lofrumento; Natasha Irrera; Domenico Santoro; Francesco Patanè; Gianluca Di Bella; Francesco Costa; Antonio Micari Journal: J Clin Med Date: 2022-04-23 Impact factor: 4.964
Authors: Leonardo De Luca; Raffaella Mistrulli; Francesco Antonio Veneziano; Francesco Grigioni; Massimo Volpe; Francesco Musumeci; Domenico Gabrielli Journal: J Clin Med Date: 2022-01-20 Impact factor: 4.241
Authors: Pascal Vranckx; Marco Valgimigli; Lars Eckardt; Thorsten Lewalter; Ramunas Unikas; Francisco Marin; François Schiele; Petra Laeis; Paul-Egbert Reimitz; Rüdiger Smolnik; Wolfgang Zierhut; Jan Tijssen; Andreas Goette Journal: Eur Heart J Date: 2020-12-14 Impact factor: 29.983
Authors: Davide Capodanno; Marco Di Maio; Antonio Greco; Deepak L Bhatt; C Michael Gibson; Andreas Goette; Renato D Lopes; Roxana Mehran; Pascal Vranckx; Dominick J Angiolillo Journal: J Am Heart Assoc Date: 2020-08-01 Impact factor: 5.501